Genloxasp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2011-09-08
Share capital
425,600.00 PLN
Activity description

Genloxa operates a personalized medicine laboratory offering calprotectin and pancreatic elastase tests in stool samples to support the diagnosis of intestinal diseases and exocrine pancreatic insufficiency. The Dose5-FU test measures 5-fluorouracil levels in blood, helping physicians individually adjust doses during chemotherapy. The laboratory also performs molecular diagnostics of markers used in the initial and advanced diagnosis of cancers for specialized oncology centers and institutional clients.

Registered address
2, 84-100 Rzucewo, Poland
Website
genloxa.pl
Opening hours
Monday–Friday
7:00–16:00
Phone
Electronic delivery address
AE:PL-55672-42313-RFEVU-33

Financials

Revenue history (in k)

Filing timeliness

2 of 6 financial statements were filed late (the longest delay 86 days for 2021).

  • 202506/07/2026
  • 202413/07/2025
  • 202309/07/2024
  • 202217/07/2023
  • 202109/10/2022
  • 202015/10/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Industry

Offer

  • Diagnostic tests
  • Calprotectin test
  • Pancreatic elastase test
  • G-test
  • Dose5-FU test
  • Molecular diagnostics

Public procurement

46 tenders recorded as contractor: 15 national ($544,519) and 31 EU ($2,020,668).

SubjectAmount
Purchase and delivery of molecular biology reagents for Laboratorium Badań Translacyjnych w Medycynie
–
Supply of reagents, including lease of analysers for ZLDK for a period of 36 months
$18,936
Reagents for specific proteins and electrophoretic techniques, including equipment rental, and reagents for autoimmune tests, reagents for a staining system and other diagnostic tests
$50,940

Trademarks

Genloxa holds 1 active trademark registered with the Polish Patent Office. 1 mark has expired or was not registered. The first mark was filed in 2011.

MarkNumberClassesStatusProtected until
GENLOXA(word)Z.4292031, 5, 35, 42, 44Protected May 26, 2034
OncotestZ.3935231, 5, 42, 44Expired –
MarkProtected until
GENLOXA(word)May 26, 2034
Oncotest–

Authorized Representatives

Artur Maksymilian Wilandt – President of the Management Board
Hanna Jolanta Wilandt – Vice President of the Management Board
Paweł Jan Schweiger – Vice President of the Management Board

Manner of representation

Each member of the management board is authorised to represent the company independently.

Ownership

OwnerSharesShare valueStake
Paweł Jan Schweigerage 42
1,064$57,482.4450%
Artur Maksymilian Wilandtage 42
532$28,741.2225%
Hanna Jolanta Wilandtage 43
532$28,741.2225%

Artur Maksymilian Wilandt and Hanna Jolanta Wilandt hold a combined 50% – the ownership structure indicates family control.

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2012-01-01.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

113 public aid cases recorded, with a total value of $966,679.

PurposeGross amount
Aid in the form of wage subsidies for employing workers with disabilities
$419
De minimis aid (in accordance with Commission Regulation 2023/2831)
$11,789
De minimis aid (in accordance with Commission Regulation 2023/2831)
$4,794

European Funds

ProjectEU co-financing
Innovative in vitro diagnostic tests to improve the effectiveness of thiopurine immunosuppressive treatment.
$783.2K

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
GenomedS.A.
Read-GeneS.A.
SkinlabP.S.A.
GenxoneS.A.
Polbiotech Laboratoriumsp. z o.o.
Zawamedsp. z o.o.
Vitagenumsp. z o.o.
Oncotherics PolandS.A.
Neobiolabsp. z o.o.
Meritrosp. z o.o.

Change history

DateEvent
2023-10-16Name change
2023-08-31Share capital increase
2023-08-31Name change
2015-09-09Share capital increase
2015-09-09PKD change

FAQ

Last updated: 2026-07-09